Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

BACKGROUND: The extent to which response and survival benefits with immunotherapy-based regimens persist informs optimal first-line treatment options. We provide long-term follow-up in patients with advanced renal cell carcinoma (aRCC) receiving first-line nivolumab plus ipilimumab (NIVO+IPI) versus...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Immunother Cancer
Huvudupphovsmän: Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2021
Ämnen:
Clinical/Translational Cancer Immunotherapy
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7359377/
https://ncbi.nlm.nih.gov/pubmed/32661118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000891
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk